Advances in myogenic cell transplantation and skeletal muscle tissue engineering
Anthony Scime1, Annabelle Z. Caron2, Guillaume Grenier2
1
Regenerative Medicine Program and Center for Stem Cell and Gene Therapy, Ottawa Health Research Institute, 501 Smyth Road, Ottawa, Ontario, Canada, K1H 8L6, 2Research Center on Aging, Faculty of Medicine, Department of Orthopedic Surgery, Universite de Sherbrooke, Quebec, Canada, J1H 4C3
TABLE OF CONTENTS
- 1. Abstract
- 2. Introduction
- 3. Skeletal muscle organization
- 4. Muscle Repair
- 5. Cellular transplantation therapy
- 5.1. Muscle-derived myogenic stem cells for transplantation therapy
- 5.1.1. Satellite cells
- 5.1.2. Muscle-derived side population (SP) cells
- 5.1.3. Adult muscle-derived CD34 positive cells
- 5.1.4. Embryonic muscle-derived CD34 positive cells
- 5.2. Non-muscle-derived myogenic stem cells for transplantation therapy
- 5.2.1. Bone marrow-derived
- 5.2.2. Mesoangioblasts
- 6. Engineered skeletal muscle tissue
- 6.1. Type of scaffold
- 6.1.1. Natural scaffold
- 6.1.2. Biocompatible polymeric scaffold
- 6.1.3. Bio-inspired adhesive polymeric scaffold
- 6.2. Current challenges
- 6.2.1. Force generation
- 6.2.2. Vascularization
- 7. Concluding Remarks
- 8. Acknowledgments
- 9. References
1. ABSTRACT
Curative treatments are currently not available for people suffering from one of the many prevalent muscle myopathies. One approach to ameliorate these conditions relies on the cell-based transplantation of potential myogenic precursors, or more optimistically, the transfer of engineered skeletal muscle tissue. To date, clinical trials with myogenic stem cell transplantation have met with only modest success while the transplantation of engineered muscle tissue is at the earliest stages of development. Despite the slow progress, these studies have provided insights and avenues that will eventually lead to a powerful therapeutic tool.
